Effect of dose intensification (DI) of octreotide-LAR (O-LAR) among symptomatic patients with neuroendocrine tumors (NETs).
Khalid S. Al Efraij
No relevant relationships to disclose
Mohammed A Aljama
No relevant relationships to disclose
Hagen F. Kennecke
Honoraria - Novartis
Research Funding - Novartis